Oral ecnoglutide tablet Clinical Trials (2026): 5 Studies for Type 2 Diabetes Mellitus & T2DM
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Oral ecnoglutide tablet clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Type 2 Diabetes Mellitus & T2DM) and 1,669 total planned enrollment. 3 Phase 3 Oral ecnoglutide tablet trials are listed. 1 Oral ecnoglutide tablet clinical trial is actively recruiting. Most recent activity: NCT07243171 (Nov 2026).
Oral ecnoglutide tablet clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 | |
| P3 | 3 | 3 |
Recruiting Oral ecnoglutide tablet clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07243171 | A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | P1/P2 | Overweight and/or Obesity | 84 | Nov 2025 |
Oral ecnoglutide tablet clinical trials by indication
T2DM (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05680129 | — | P3 | completed | A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM |
| NCT05680155 | — | P3 | completed | A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients |
Overweight and/or Obesity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07243171 | — | P1/P2 | recruiting | A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity |
Weight Management (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05813795 | — | P3 | completed | A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity |
Obesity (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05184322 | — | P1 | completed | XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults |
All Oral ecnoglutide tablet trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07243171 | A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | P1/P2 | recruiting | 84 | Hangzhou Sciwind Biosciences Co., Ltd. | Nov 2025 | |
| NCT05184322 | XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults | P1 | completed | 87 | Sciwind Biosciences APAC CO Pty. Ltd. | Apr 2022 | |
| NCT05680129 | A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM | P3 | completed | 623 | Hangzhou Sciwind Biosciences Co., Ltd. | Jan 2023 | |
| NCT05680155 | A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients | P3 | completed | 211 | Hangzhou Sciwind Biosciences Co., Ltd. | Dec 2022 | |
| NCT05813795 | A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity | P3 | completed | 664 | Hangzhou Sciwind Biosciences Co., Ltd. | Apr 2023 |
Oral ecnoglutide tablet clinical trials: frequently asked questions
- How many Oral ecnoglutide tablet clinical trials are there?
- 5 Oral ecnoglutide tablet clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 4 are marked completed.
- Are Oral ecnoglutide tablet clinical trials recruiting in 2026?
- Yes — 1 Oral ecnoglutide tablet trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Oral ecnoglutide tablet being studied for?
- Oral ecnoglutide tablet is being studied for Type 2 Diabetes Mellitus, T2DM, Weight Management, Obesity, Overweight and/or Obesity. The trials are grouped by indication on this page.
- What phase is Oral ecnoglutide tablet in?
- Oral ecnoglutide tablet clinical trials span 3 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Oral ecnoglutide tablet clinical trials?
- The lead sponsor across the most Oral ecnoglutide tablet trials is Hangzhou Sciwind Biosciences Co., Ltd., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Oral ecnoglutide tabletas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: